---
layout: default
title: Vecuronium
parent: Model Prediction Only (L5)
nav_order: 876
evidence_level: L5
indication_count: 10
---

# Vecuronium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Vecuronium: From Anesthesia Muscle Relaxant to Insomnia

## One-Sentence Summary

Vecuronium is a non-depolarizing neuromuscular blocking agent used as a muscle-relaxant adjunct during general anesthesia and endotracheal intubation.
The TxGNN model predicts it may be effective for **Insomnia**, but this direction is currently supported only by **1 indirectly related clinical trial** and **no disease-specific literature**, and the model's own mechanistic reasoning finds no biological link between the two.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file — no approved indication text available (drug not marketed in India); role described across the evidence pack is as a perioperative neuromuscular blocking agent |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

A formal mechanism-of-action record for Vecuronium is flagged as a data gap (DG002) in this pack. However, the evidence pack's own repurposing rationale consistently describes Vecuronium as a **non-depolarizing neuromuscular blocker acting on nicotinic acetylcholine receptors (nAChR) at the skeletal muscle motor end plate** — a peripheral mechanism used to achieve muscle relaxation for surgical procedures and airway management, with no established action on central nervous system sleep-wake regulation pathways.

Insomnia is governed by CNS circuits (e.g., GABAergic, orexin, melatonergic signaling), which is mechanistically unrelated to peripheral neuromuscular blockade. The evidence pack explicitly states: *"與失眠無合理生物學關聯"* (no plausible biological relationship to insomnia).

The most likely explanation for the high TxGNN score is **knowledge-graph co-occurrence bias**: Vecuronium is a near-ubiquitous adjunct in general anesthesia records, and such records frequently co-occur with peri-/post-operative sleep disturbance or insomnia codes — creating a statistical association without a causal pharmacological basis. This pattern is not unique to insomnia: all 10 indications ranked for Vecuronium in this pack carry the same "Hold" recommendation, and their supporting "evidence" is almost entirely unrelated anesthesia-procedure trials (e.g., pediatric PK studies, RSI reviews, general anesthesia technique papers) rather than disease-targeted research.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3,520 | Pediatric pharmacokinetics study of understudied drugs administered per standard of care; Vecuronium included only as a routine anesthesia agent, not as an insomnia treatment (relevance grade C: "兒童麻醉藥動學研究，非治療失眠之試驗") |

## Literature Evidence

Currently no related literature available.

## India Market Information

Vecuronium currently has no marketing authorization on file in India (Market Status: Not Marketed; 0 registrations).

## Safety Considerations

Please refer to the package insert for safety information. (TFDA/CDSCO label warnings and contraindications are not yet available in this dataset — flagged as a blocking data gap, DG001; DDI query returned no results.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no plausible mechanistic link between Vecuronium's peripheral neuromuscular action and insomnia; the only supporting clinical trial is an unrelated pediatric pharmacokinetics study, and evidence level is L5 (model prediction only, no confirmatory studies). This pattern — weak/absent mechanistic support across all 10 ranked predictions — is consistent with knowledge-graph co-occurrence bias rather than genuine repurposing signal.

**To proceed, the following is needed:**
- TFDA/CDSCO package insert data (warnings, contraindications) — currently a blocking gap (DG001)
- Confirmed original mechanism-of-action documentation from DrugBank (DG002)
- Any preclinical or mechanistic study establishing a CNS/sleep-pathway effect for Vecuronium, if one exists
- Re-screening of the full 10-indication candidate list for this drug, given the systematic co-occurrence bias observed, before allocating further review resources
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

